Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 6/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 4/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | PPARG | P37231 | 2/20 | 0.41 |
| ▸ | PPARA | Q07869 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5101224 | 0.81 | PPARG (0.49) | LTA4HMAPTLMNARXFP1TSHR | |
| SCHEMBL5443755 | 0.80 | TSHR (0.48) | MAPTLMNARXFP1TSHRHPGD | |
| SCHEMBL14265752 | 0.80 | PPARG (0.58) | MAPTLMNARXFP1PPARGPPARA | |
| SCHEMBL5107137 | 0.80 | PPARG (0.58) | MAPTLMNARXFP1PPARGPPARA | |
| SCHEMBL5107151 | 0.79 | PPARG (0.57) | MAPTLMNARXFP1TSHRPPARG | |
| SCHEMBL5107495 | 0.79 | MAPT (0.46) | LTA4HMAPTLMNARXFP1TSHR | |
| SCHEMBL5107504 | 0.79 | MAPT (0.46) | LTA4HMAPTLMNARXFP1TSHR | |
| SCHEMBL5140361 | 0.79 | MAPT (0.46) | LTA4HMAPTLMNARXFP1TSHR | |
| SCHEMBL14265693 | 0.79 | MAPT (0.46) | LTA4HMAPTLMNARXFP1TSHR | |
| SCHEMBL14360396 | 0.78 | PPARA (0.44) | LTA4HMAPTLMNARXFP1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070275956-A1 | Novel Heterocyclic Compounds | CADILA HEALTHCARE LIMITED (IN) | 2007-11-29 | — | — | US | disclosed |
| US-20070275956-A1 | Novel Heterocyclic Compounds | CADILA HEALTHCARE LIMITED (IN) | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275956-A1 | Novel Heterocyclic Compounds | CYP46A1, DHCR7, NPC1L1 | LTA4H 374/4885MAPT 162/4885LMNA 949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.